Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

被引:0
作者
Lohit Garg
Manasvi Gupta
Syed Rafay Ali Sabzwari
Sahil Agrawal
Manyoo Agarwal
Talha Nazir
Jeffrey Gordon
Babak Bozorgnia
Matthew W. Martinez
机构
[1] Lehigh Valley Health Network,Division of Cardiology
[2] Maulana Azad Medical College,Division of Cardiology
[3] Brown University,Department of Internal Medicine
[4] The University of Tennessee Health Science Center,undefined
来源
Heart Failure Reviews | 2019年 / 24卷
关键词
Atrial fibrillation; Hypertrophic cardiomyopathy; Treatment; Antiarrhythmic agents;
D O I
暂无
中图分类号
学科分类号
摘要
Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.
引用
收藏
页码:189 / 197
页数:8
相关论文
共 622 条
[1]  
Jacoby D(2012)Genetics of inherited cardiomyopathy Eur Heart J 33 296-304
[2]  
McKenna WJ(2015)Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations Cardiovasc Res 105 409-423
[3]  
Olivotto I(2014)ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J 35 2733-2779
[4]  
d’Amati G(2011)American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure S
[5]  
Basso C(2017)Hypertrophic Cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy Circ Res 121 749-770
[6]  
Elliott PM(2016)Management of atrial fibrillation in hypertrophic cardiomyopathy Circulation 133 1901-1905
[7]  
Anastasakis A(2001)Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy Circulation 104 2517-2524
[8]  
Gersh BJ(2014)Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review Heart 100 465-472
[9]  
Maron BJ(1990)Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study J Am Coll Cardiol 15 1279-1285
[10]  
Bonow RO(2012)Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives J Am Coll Cardiol 60 705-715